Drug Price Trends for ENILLORING VAGINAL RING

Average Pharmacy Cost for ENILLORING VAGINAL RING

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ENILLORING VAGINAL RING	70700-0156-11	50.04303	EACH	2026-03-18
ENILLORING VAGINAL RING	70700-0156-91	50.04303	EACH	2026-03-18
ENILLORING VAGINAL RING	70700-0156-11	50.51333	EACH	2026-02-18
ENILLORING VAGINAL RING	70700-0156-91	50.51333	EACH	2026-02-18

Market analysis and price projections for Enilloring Vaginal Ring

Last updated: February 13, 2026

Overview
Enilloring Vaginal Ring (EVR) is a hormonal contraceptive product designed for vaginal use, primarily targeting women seeking long-acting reversible contraception (LARC). Its market presence hinges on its efficacy, safety profile, manufacturing costs, regulatory approvals, and competitive landscape.

Market Size & Growth Potential
The global contraceptives market reached approximately $19.2 billion in 2022, with a compound annual growth rate (CAGR) of 4.5% forecasted through 2030 (source: Fortune Business Insights). The vaginal ring segment comprises an estimated 15-20% of this market, valued at roughly $2.9 billion in 2022.

Factors influencing growth include increased awareness about family planning, rising approval of new contraceptives, and women’s preference for discreet methods. In particular, emerging markets in Asia, Africa, and Latin America demonstrate higher adoption potential due to expanding healthcare infrastructure.

Competitive Landscape
Key products include:

• NuvaRing (Merck & Co.): Dominates with a global market share exceeding 70%.
• Annovera (TherapeuticsMD): Offers a one-year reusable vaginal ring, gaining traction in North America.
• Candidate Products: Several generic and biosimilar options in development.

The entry of new products like EVR could disrupt existing dynamics if it demonstrates advantages in cost, ease of use, or safety.

Regulatory and Patent Outlook
EVR’s regulatory pathway depends on regional agencies (FDA, EMA, etc.). Patent status influences pricing; exclusivity periods extend until approximately 2030 for key formulations. Generic competition anticipated post-patent expiry could prompt price reductions.

Cost Structure & Pricing

Cost Component	Estimated Percentage	Notes
Manufacturing	20-30%	Dependent on scale and technology
Distribution & Logistics	10-15%	Varies by region
Regulatory & Compliance	5-10%	Cost of approvals and post-market surveillance
Marketing & Sales	15-20%	Regional variations included
Profit Margin	25-30%	Industry standard for pharmaceuticals

Initial Price Projections
Currently, the price of NuvaRing varies between $50-$70 per month in developed markets. EVR aims to position itself competitively within the $20-$40 monthly range, similar to the cost of generic hormonal contraceptives.

Projected annual revenue for EVR, assuming:

• Adoption rate of 10-15% within the contraceptive ring market by 2030.
• An initial market penetration of 2 million users in North America, Europe, and select Asian markets.
• Average selling price (ASP) of $30 per month.

Revenue estimation:
2 million users x $30/month x 12 months = $720 million annually at maximum penetration.

Price Trends & Future Outlook
With patent expiration, generic entries are likely to push prices down by as much as 30-50%. Market competition will influence long-term ASPs, potentially bringing prices to $10-$20 per month in low-income regions.

Emerging delivery options, such as bio-compatible implants or self-inserted devices, may challenge EVR’s market share, compelling price adjustments to maintain competitiveness.

Regulatory & Market Entry Risks
Delays in approval, clinical trial failures, or safety concerns can significantly affect commercial viability. The regional variation in contraceptive use and acceptability also influences market penetration and pricing.

Key Takeaways

• The vaginal ring market is projected to reach approximately $3 billion by 2030, with contraceptives accounting for a significant share.
• EVR’s success depends on regulatory approval, manufacturing costs, and competitive dynamics.
• Current pricing aims for $20-$40 per month; future prices may decline following patent expiry and market entry of generics.
• Revenue potential hinges on adoption rates, regional market access, and competitor responses.
• Market risks include regulatory hurdles, safety profiles, and changing consumer preferences.

FAQs

1. What factors influence pricing for vaginal contraceptive rings?
   Pricing depends on manufacturing costs, regulatory expenses, competitive landscape, and regional market conditions.

2. How does patent expiration affect vaginal ring prices?
   Patent expiration opens markets for generics, typically reducing prices by 30-50%.

3. What is the main competition for EVR?
   NuvaRing and Annovera are the primary competitors, with NuvaRing holding dominant market share.

4. Are there regulatory challenges that could impact EVR?
   Yes, including approval delays, safety concerns, and regional regulatory requirements.

5. What is the expected market growth for vaginal rings?
   The segment is expected to grow at a CAGR of approximately 4.5% through 2030, reflecting increasing acceptance and new product launches.

---

References
[1] Fortune Business Insights, "Global Contraceptives Market," 2022.